Intellia Therapeutics, Inc. (NASDAQ:NTLA) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating on Intellia Therapeutics, Inc. (NASDAQ:NTLA) while boosting its price target to $25 from $15 on January 28, following the removal of a clinical hold on the company’s MAGNITUDE-2 study.
Pixabay/Public Domain
The updated protocol raises the target enrollment to around 60 patients from the originally intended 50, implying a focus on improving risk mitigation and data comprehension rather than discontinuing the drug altogether.
H.C. Wainwright highlighted that the safety incidents that triggered the hold were uncommon, with two Grade 4/5 liver incidents, one of which was fatal, occurring in about 450 treated patients, accounting for less than 0.5% of the group.
Intellia Therapeutics, Inc. is a biotech company at the forefront of CRISPR-Cas9 gene-editing technology, developing cutting-edge treatments for both in vivo and ex vivo applications. Its main initiative, NTLA-2001, aims to treat transthyretin amyloidosis, an incurable disease.
READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.
This article is originally published at Insider Monkey.
